From the source
OpenAI has acquired Orchestra Bio, a startup that helps pharma teams coordinate drug development, and will fold it into Rosalind, its AI platform for life sciences.
- The combined effort is meant to build AI agents that link scientific findings with clinical trials, decisions and next steps so new drugs reach patients faster.
- Developing a drug in the US takes ten to 15 years on average, and siloed systems plus constant back-and-forth between internal teams and outside partners slow things down.
- Orchestra's agents track trials, flag affected timelines when something goes wrong such as a failed production batch, and surface options for what to do next, which could free scientists to focus on decisions and the actual research.
- Rosalind includes GPT-Rosalind, which helps researchers analyze biological and chemical questions, and Rosalind Workbench, which connects those capabilities with scientific data and tools.
- OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research, and financial terms of the deal weren't disclosed.